BACKGROUND: Intestinal inflammation associated with inflammatory bowel disease (IBD) is typically characterized by an inflammatory cell infiltrate and pro-inflammatory cytokine production. Of particular interest, the frequency of colony stimulating factor-1 (CSF-l)-expressing cells is increased in active lesions. In this study, we have investigated the role of CSF-1 in mucosal inflammation, using a murine model of colitis induced by dextran sulfate sodium (DSS). METHODS: A neutralizing anti-CSF-1 antibody was administered to Balb/c mice that received DSS in their drinking water. Signs of colitis, such as clinical disease score, cellular infiltrate, and cytokine production, were assessed. RESULTS: Administration of a neutralizing anti-CSF-1 antibody significantly inhibited DSS-induced colitis. Clinical symptoms, such as weight loss and the appearance of diarrhea or fecal blood, were reduced by CSF-1 blockade; histologic scores were also improved. The cellular infiltrate of macrophages and T cells was inhibited and a trend toward reduced production of pro-inflammatory cytokines was noted. CONCLUSIONS: This is the first study to demonstrate that CSF-1 plays an important role in mediating intestinal mucosal inflammation and therefore may prove to be an attractive therapeutic target for intestinal diseases such as inflammatory bowel disease.
BACKGROUND: Intestinal inflammation associated with inflammatory bowel disease (IBD) is typically characterized by an inflammatory cell infiltrate and pro-inflammatory cytokine production. Of particular interest, the frequency of colony stimulating factor-1 (CSF-l)-expressing cells is increased in active lesions. In this study, we have investigated the role of CSF-1 in mucosal inflammation, using a murine model of colitis induced by dextran sulfate sodium (DSS). METHODS: A neutralizing anti-CSF-1 antibody was administered to Balb/c mice that received DSS in their drinking water. Signs of colitis, such as clinical disease score, cellular infiltrate, and cytokine production, were assessed. RESULTS: Administration of a neutralizing anti-CSF-1 antibody significantly inhibited DSS-induced colitis. Clinical symptoms, such as weight loss and the appearance of diarrhea or fecal blood, were reduced by CSF-1 blockade; histologic scores were also improved. The cellular infiltrate of macrophages and T cells was inhibited and a trend toward reduced production of pro-inflammatory cytokines was noted. CONCLUSIONS: This is the first study to demonstrate that CSF-1 plays an important role in mediating intestinal mucosal inflammation and therefore may prove to be an attractive therapeutic target for intestinal diseases such as inflammatory bowel disease.
Authors: Ronaldo Lira-Junior; Mayla K S Teixeira; Eduardo J V Lourenço; Daniel M Telles; Carlos Marcelo Figueredo; Elisabeth A Boström Journal: Clin Oral Investig Date: 2019-05-17 Impact factor: 3.573
Authors: Ariel Munitz; Eric T Cole; Amanda Beichler; Katherine Groschwitz; Richard Ahrens; Kris Steinbrecher; Tara Willson; Xiaonan Han; Lee Denson; Marc E Rothenberg; Simon P Hogan Journal: Gastroenterology Date: 2010-04-14 Impact factor: 22.682
Authors: Ahmed Al-Dwairi; Mohammad Alqudah; Othman Al-Shboul; Mahmoud Alfaqih; Dana Alomari Journal: Exp Ther Med Date: 2018-05-25 Impact factor: 2.447
Authors: Stacey Meeker; Audrey Seamons; Jisun Paik; Piper M Treuting; Thea Brabb; William M Grady; Lillian Maggio-Price Journal: Cancer Res Date: 2014-06-17 Impact factor: 12.701
Authors: Duy Huynh; Xu-Ming Dai; Sayan Nandi; Sally Lightowler; Melanie Trivett; Chee-Kai Chan; Ivan Bertoncello; Robert G Ramsay; E Richard Stanley Journal: Gastroenterology Date: 2009-03-18 Impact factor: 22.682